OpenAI has announced that it is acquiring Orchestra Bio in a strategic expansion into the biotechnology sector. According to the company, the acquisition aims to bring AI-powered operations directly into life sciences research and development. The initiative focuses on providing specialized technological support to organizations conducting scientific research.
The central objective of the transaction is to support biopharma teams as they work to accelerate drug development. Furthermore, OpenAI stated that the implementation is intended to advance new treatments in the medical field. The acquisition establishes a direct application of the company's technology within pharmaceutical workflows.